EUI-1217244467v4 Contract number (FI No): 89427 Contract number (FI No): 89987 Serapis No: 2018-0245 NANOBIOTIX EGFF Amendment Agreement n°2 in relation to the Finance Contract signed on 26 July 2018, as amended by an amendment agreement dated 18...Amendment Agreement • April 24th, 2024 • Nanobiotix S.A. • Pharmaceutical preparations
EUI-1217246584v3 DATED 18 APRIL 2024 Contract number (FI No): 89427 Contract number (FI No): 89987 Serapis No: 2018-0245 EUROPEAN INVESTMENT BANK (the Bank) - and - NANOBIOTIX (the Company) AMENDMENT AGREEMENT N°2 RELATING TO A ROYALTY AGREEMENT DATED...Royalty Agreement • April 24th, 2024 • Nanobiotix S.A. • Pharmaceutical preparations
ContractNovation Agreement • April 24th, 2024 • Nanobiotix S.A. • Pharmaceutical preparations
LICENSE AGREEMENT BY AND BETWEENLicense Agreement • April 24th, 2024 • Nanobiotix S.A. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is entered into as of July 7, 2023 (the “Execution Date”) by and between Nanobiotix S.A., a French société anonyme having its registered office located at 60 Rue de Wattignies, 75012, Paris, France, registered under number 447 521 600 (RCS Paris) (“Nanobiotix”), on the one hand, and Janssen Pharmaceutica NV, a limited liability company organized under the laws of Belgium, registered under company number 0403.834.160, and having its registered office at Turnhoutseweg 30; 2340 Beerse Belgium (“Janssen”), on the other hand. Nanobiotix and Janssen are referred to in this Agreement each individually as a “Party” and collectively as the “Parties.”
Execution Version REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of September 11, 2023 by and among Nanobiotix S.A., a limited company incorporated under the law of France (the...Registration Rights Agreement • April 24th, 2024 • Nanobiotix S.A. • Pharmaceutical preparations
